OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
FOHE59

Fortis Healthcare Ltd

Healthcare Facilities & ServicesVerified

Fortis Healthcare Ltd maintains a debt-to-equity ratio of 0.28, indicating a relatively conservative capital structure. The company's liquidity position is characterized as medium, with a current ratio of 0.92, suggesting that it has nearly equal current assets to current liabilities. The company's free cash flow of 2,391,891,000 INR indicates a positive cash flow from operations after capital expenditures, which supports its liquidity position. In terms of profitability, Fortis Healthcare Ltd reports a return on equity of 8.68% and a return on assets of 5.65%. These figures are below the industry median for return on equity and return on assets, suggesting that the company's profitability is not as strong as its peers. The company's operating income of 11,137,531,000 INR and net income of 7,742,152,000 INR reflect its ability to generate earnings, but the gross profit margin of 73.5% indicates that the company is managing its costs effectively. Fortis Healthcare Ltd's revenue is concentrated in its core healthcare services and equipment segment, with no significant geographic diversification reported. The company's total revenue of 77,827,521,000 INR is primarily derived from its operations in India, with no material exposure to international markets. This concentration may pose a risk if the domestic market experiences economic downturns or regulatory changes. The company's growth trajectory is expected to be moderate, with no significant revenue growth projected in the next fiscal year. The capital expenditure of -8,469,378,000 INR indicates that the company is investing in its operations, which could support future growth. However, the company's free cash flow and operating cash flow of 2,391,891,000 INR and 14,239,319,000 INR, respectively, suggest that it has the financial flexibility to fund its operations and investments. The risk assessment for Fortis Healthcare Ltd indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to meet short-term obligations. The company's dilution risk is low, with no significant dilution potential reported. The company's capital structure and financial flexibility are key factors in managing its risk profile. Recent events and filings for Fortis Healthcare Ltd include analyst estimates that suggest a mean price target of 1,064.12 INR and a median price target of 1,075.00 INR. The mean recommendation from analysts is 1.94, indicating a generally positive outlook. The company has received a strong-buy rating from 6 analysts and a buy rating from 6 analysts, with 3 analysts recommending a hold. These analyst ratings reflect the market's confidence in the company's future performance.

30-day price · FOHE+168.65 (+21.2%)
Low$766.80High$982.95Close$963.65As of15 May, 00:00 UTC
Profile
CompanyFortis Healthcare Ltd
TickerFOHE.NS
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Fortis Healthcare Ltd operates as a provider of healthcare services and equipment, generating revenue primarily through its operations in healthcare facilities and services.

Classification. Fortis Healthcare Ltd is classified under the Healthcare economic sector, Healthcare Services & Equipment business sector, and Healthcare Facilities & Services industry with a confidence level of 0.92.

Fortis Healthcare Ltd maintains a debt-to-equity ratio of 0.28, indicating a relatively conservative capital structure. The company's liquidity position is characterized as medium, with a current ratio of 0.92, suggesting that it has nearly equal current assets to current liabilities. The company's free cash flow of 2,391,891,000 INR indicates a positive cash flow from operations after capital expenditures, which supports its liquidity position. In terms of profitability, Fortis Healthcare Ltd reports a return on equity of 8.68% and a return on assets of 5.65%. These figures are below the industry median for return on equity and return on assets, suggesting that the company's profitability is not as strong as its peers. The company's operating income of 11,137,531,000 INR and net income of 7,742,152,000 INR reflect its ability to generate earnings, but the gross profit margin of 73.5% indicates that the company is managing its costs effectively. Fortis Healthcare Ltd's revenue is concentrated in its core healthcare services and equipment segment, with no significant geographic diversification reported. The company's total revenue of 77,827,521,000 INR is primarily derived from its operations in India, with no material exposure to international markets. This concentration may pose a risk if the domestic market experiences economic downturns or regulatory changes. The company's growth trajectory is expected to be moderate, with no significant revenue growth projected in the next fiscal year. The capital expenditure of -8,469,378,000 INR indicates that the company is investing in its operations, which could support future growth. However, the company's free cash flow and operating cash flow of 2,391,891,000 INR and 14,239,319,000 INR, respectively, suggest that it has the financial flexibility to fund its operations and investments. The risk assessment for Fortis Healthcare Ltd indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to meet short-term obligations. The company's dilution risk is low, with no significant dilution potential reported. The company's capital structure and financial flexibility are key factors in managing its risk profile. Recent events and filings for Fortis Healthcare Ltd include analyst estimates that suggest a mean price target of 1,064.12 INR and a median price target of 1,075.00 INR. The mean recommendation from analysts is 1.94, indicating a generally positive outlook. The company has received a strong-buy rating from 6 analysts and a buy rating from 6 analysts, with 3 analysts recommending a hold. These analyst ratings reflect the market's confidence in the company's future performance.
Key takeaways
  • Fortis Healthcare Ltd has a conservative capital structure with a debt-to-equity ratio of 0.28.
  • The company's return on equity of 8.68% is below the industry median, indicating lower profitability compared to peers.
  • Fortis Healthcare Ltd's revenue is concentrated in its core healthcare services and equipment segment, with no significant geographic diversification.
  • The company's liquidity position is characterized as medium, with a current ratio of 0.92.
  • Analyst estimates suggest a generally positive outlook for Fortis Healthcare Ltd, with a mean price target of 1,064.12 INR and a median price target of 1,075.00 INR.
  • # RATIONALES
  • **margin_outlook_rationale**: The company's gross profit margin of 73.5% indicates effective cost management, which supports a stable margin outlook.
  • **rd_outlook_rationale**: No specific information is provided regarding the company's research and development activities or their impact on future performance.
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$77.83B
Gross profit$57.16B
Operating income$11.14B
Net income$7.74B
R&D
SG&A
D&A
SBC
Operating cash flow$14.24B
CapEx-$8.47B
Free cash flow$2.39B
Total assets$136.92B
Total liabilities$47.75B
Total equity$89.17B
Cash & equivalents$799.2M
Long-term debt$24.75B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$89.17B
Net cash-$23.95B
Current ratio0.9
Debt/Equity0.3
ROA5.7%
ROE8.7%
Cash conversion1.8%
CapEx/Revenue-10.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricFOHEActivity
Op margin14.3%7.7% medp25 -2.4% · p75 15.5%above median
Net margin9.9%5.9% medp25 -3.8% · p75 12.8%above median
Gross margin73.4%45.5% medp25 31.1% · p75 62.9%top quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-10.9%-7.0% medp25 -14.9% · p75 -3.2%below median
Debt / equity28.0%25.0% medp25 3.8% · p75 63.3%above median
Observations
IR observations
Mean price target1,064.12 INR
Median price target1,075.00 INR
High price target1,206.00 INR
Low price target875.00 INR
Mean recommendation1.94 (1=strong buy, 5=strong sell)
Strong-buy count6.00
Buy count6.00
Hold count3.00
Sell count1.00
Strong-sell count0.00
Mean EPS estimate14.11 INR
Last actual EPS11.44 INR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 02:42 UTC#126c85dd
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 23:20 UTCJob: e8d4b521